Literature DB >> 23179755

The summary on non-reactivation cholinergic properties of oxime reactivators: the interaction with muscarinic and nicotinic receptors.

O Soukup1, D Jun, G Tobin, K Kuca.   

Abstract

Organophosphorus inhibitors (OP) of acetylcholinesterase (AChE) represent a group of highly toxic compounds. The treatment of OP intoxication is, however, insufficiently ensured. Currently, two main categories of drugs-anticholinergics and oxime reactivators- are employed as antidotes. Oximes have been reported to act at several levels of the cholinergic transmission, and among the non-reactivation effects, the interaction with cholinergic receptors stands out. This review addresses issues correlated with non-reactivating effects of oxime reactivators with a special focus on the muscarinic and nicotinic receptors, but involvement of other cholinergic structures such as AChE and choline uptake carriers are discussed too. It can be concluded that the oxime reactivators show a variation in their antagonistic effect on the muscarinic and nicotinic receptors, which is likely to be of significance in the treatment of OP poisoning. In vitro data reported oximes to exert higher efficacy on the muscarinic M2 subtype than on the AChE. However, this effect seemed to be subtype specific since the antagonistic M3 effect was lower. Also, and importantly, the antimuscarinic effect was larger than that on nicotinic receptors. Even though atropine showed a much higher muscarinic antagonism, it is supposed that non-reactivation properties of oxime reactivators play a significant role in the treatment of OP poisoning.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179755     DOI: 10.1007/s00204-012-0977-1

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  7 in total

1.  A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides.

Authors:  Christina M Wilhelm; Thomas H Snider; Michael C Babin; David A Jett; Gennady E Platoff; David T Yeung
Journal:  Toxicol Appl Pharmacol       Date:  2014-10-31       Impact factor: 4.219

2.  Protective effects of the antihistamine promethazine aginst acute paraxon-methyl and dicrotophos toxicity in adult rats.

Authors:  Syed M Nurulain; Shreesh Ojha; Mohammad Shafiullah; Nadia Khan; Murat Oz; Bassem Sadek
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Toxic Injury to Muscle Tissue of Rats Following Acute Oximes Exposure.

Authors:  Vesna Jaćević; Eugenie Nepovimova; Kamil Kuča
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

4.  Design, synthesis, in silico studies and in vitro evaluation of isatin-pyridine oximes hybrids as novel acetylcholinesterase reactivators.

Authors:  Daniel A S Kitagawa; Rafael B Rodrigues; Thiago N Silva; Wellington V Dos Santos; Vinicius C V da Rocha; Joyce S F D de Almeida; Leandro B Bernardo; Taynara Carvalho-Silva; Cintia N Ferreira; Angelo A T da Silva; Alessandro B C Simas; Eugenie Nepovimova; Kamil Kuča; Tanos C C França; Samir F de A Cavalcante
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 5.  Signalling molecules in the urothelium.

Authors:  Michael Winder; Gunnar Tobin; Daša Zupančič; Rok Romih
Journal:  Biomed Res Int       Date:  2014-08-10       Impact factor: 3.411

Review 6.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

7.  Activation of (un)regulated cell death as a new perspective for bispyridinium and imidazolium oximes.

Authors:  Antonio Zandona; Nikola Maraković; Petra Mišetić; Josip Madunić; Katarina Miš; Jasna Padovan; Sergej Pirkmajer; Maja Katalinić
Journal:  Arch Toxicol       Date:  2021-06-26       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.